Show simple item record

dc.contributor.authorPrelaj, Arsela
dc.contributor.authorTay, Rebecca
dc.contributor.authorFerrara, R
dc.contributor.authorChaput, N
dc.contributor.authorBesse, B
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2019-01-10T13:02:04Z
dc.date.available2019-01-10T13:02:04Z
dc.date.issued2018en
dc.identifier.citationPrelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2018 Dec 4;106:144-59.en
dc.identifier.pmid30528799en
dc.identifier.doi10.1016/j.ejca.2018.11.002en
dc.identifier.urihttp://hdl.handle.net/10541/621455
dc.description.abstractImmune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ejca.2018.11.002en
dc.titlePredictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK;en
dc.identifier.journalEur J Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record